shRNA Vector Inhibits Intravitreal Neovascularization in Retinopathy of Prematurity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinopathy of prematurity (ROP) and other proliferative retinopathies associated with intravitreal neovascularization, such as laser ablation and anti-VEGF agents, have limitations including damaging the developing retina, causing persistent avascular retina, and raising safety concerns, while existing methods to promote physiologic retinal vascular development can worsen neovascularization.
Innovation Solution
Administration of a composition comprising a vector with a polymerase II promoter and a short hairpin RNA (shRNA) embedded in a microRNA construct, specifically targeting STAT3, VEGFR2, or EPOR mRNA sequences via subretinal injection to inhibit neovascularization without interfering with physiologic retinal vascular development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If laser ablation is used to treat intravitreal neovascularization, then neovascularization is reduced, but the developing retina is damaged
Solution Approach 1:
The patent uses shRNA molecules as intermediaries to deliver gene silencing activity specifically to neovascular endothelial cells. The shRNA targets VEGF mRNA, acting as a mediator that selectively inhibits the pathological neovascularization process without directly damaging the retina, thus resolving the contradiction between reducing neovascularization and preserving retinal development
Solution Approach 2:
The invention achieves local specificity by designing shRNA that selectively targets VEGF expression in neovascular endothelial cells. The gene silencing effect is localized to the pathological neovascular tissue rather than affecting the entire retina, allowing treatment of neovascularization while preserving normal retinal development
2Object-generated harmful factors
If anti-VEGF agents are administered to inhibit neovascularization, then intravitreal neovascularization is reduced, but persistent avascular retina occurs
Solution Approach 1:
The shRNA-mediated gene silencing provides partial and controlled inhibition of VEGF expression, specifically targeting the excessive VEGF production in neovascular endothelial cells while leaving normal physiological VEGF levels sufficient for retinal vascular development. This partial action approach prevents both neovascularization and persistent avascular retina
Solution Approach 2:
The invention changes the parameter of VEGF expression levels selectively in neovascular tissue through shRNA-mediated gene silencing. By reducing VEGF mRNA levels specifically in pathological neovascular endothelial cells while maintaining normal levels in developing retina, the treatment achieves inhibition of neovascularization without causing persistent avascular retina
3Stability of the object's composition
If agents promoting physiologic retinal vascular development are used, then retinal vascularization is improved, but intravitreal neovascularization is worsened
Solution Approach 1:
The shRNA acts as a selective intermediary that differentiates between physiological and pathological VEGF signaling. By specifically silencing VEGF in neovascular endothelial cells while leaving other retinal cells unaffected, the treatment allows normal retinal vascular development to proceed while blocking pathological neovascularization
Solution Approach 2:
The gene silencing effect is spatially localized to neovascular endothelial cells through selective shRNA uptake and processing. This local quality approach allows physiological VEGF-mediated retinal vascular development in normal tissue while blocking pathological VEGF-driven neovascularization in abnormal tissue
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively inhibits intravitreal neovascularization, reduces retinal vascular density, and improves vascular morphology without affecting normal retinal development, offering a safer and more targeted treatment for ROP and other proliferative retinopathies.
Implementation Method 1
the first shRNA has a sense RNA strand and an antisense RNA strand, wherein the sense and the antisense RNA strands form an RNA duplex, wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in STAT3, VEGFR2, or EPOR mRNA
Data Source
AI summary
Disclosed are vectors and compositions comprising a pol II promoter and an shRNA wherein the shRNA has a sense RNA strand and an antisense RNA strand, wherein the sense and the antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in STAT3, VEGFR, or EPOR. Also disclosed are methods of treating retinopathy of prematurity (ROP), methods of inhibiting expression of STAT3, VEGFR, and EPOR, and methods of regulating signaling events associated with intravitreal neovascularization (IVNV).